Cryoport Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue grew 16% year-over-year to $47.8M, with strong double-digit gains across both Life Sciences Services and Products. Full-year guidance was raised to $192–$196M, and positive adjusted EBITDA is expected in the second half, driven by robust demand and operational improvements.
Fiscal Year 2025
-
Full year 2025 revenue reached $176.2M, exceeding guidance, with strong growth in commercial cell and gene therapy and life sciences services. 2026 guidance is $190–$194M, with positive adjusted EBITDA expected in H2 2026.
-
Double-digit revenue growth continued in both core segments, with commercial cell and gene therapy revenue up 36% year-over-year. Updated 2025 revenue guidance to $170–$174 million, targeting positive adjusted EBITDA by year-end, and significant operating leverage expected in 2026–2027.
-
Double-digit revenue growth in Q2 2025 was driven by strong gains in Life Sciences Services and Products, improved margins, and a transformative partnership with DHL. Guidance for 2025 is reaffirmed, with a robust balance sheet and continued leadership in cell and gene therapy supply chain solutions.
-
Q1 revenue grew 10% year-over-year to $41M, led by 17% growth in life sciences services and 33% growth in commercial cell and gene therapy revenue. Strategic partnership with DHL and the sale of CryoPDP for $195M will strengthen global reach and financials. FY25 revenue guidance is $165M–$172M.
-
A strategic partnership with DHL, including the sale of CRYOPDP for $195 million, will accelerate growth, enhance global reach, and improve margins, with 2025 revenue guidance set at $165–$173 million. The move sharpens focus on cell and gene therapy and strengthens financial flexibility.
Fiscal Year 2024
-
2024 revenue reached $228.4M, with strong growth in life sciences services and commercial cell and gene therapy. Gross margin improved to 45.8% in Q4, and 2025 guidance is $240–$250M with a return to positive adjusted EBITDA expected.
-
Life Sciences Services drove Q3 growth with improved margins, while Products faced ongoing softness but remained profitable. Cost reductions and new service launches supported positive cash flow, and full-year guidance was reaffirmed amid sector headwinds.
-
Sequential revenue growth was achieved across all business units, with cell and gene therapy services up 51% year-over-year. Cost reduction and capital realignment initiatives are on track, supporting a revised 2024 revenue outlook of $225–$235 million and a return to positive Adjusted EBITDA in 2025.